Adrenocortical carcinoma: experience in 45 patients
Related Experiment Video
Updated: Oct 31, 2026

A Novel Method: Super-selective Adrenal Venous Sampling
Published on: September 15, 2017
Abstract:
Forty-five patients with adrenocortical carcinoma (13 nonfunctioning and 32 functioning carcinomas) were retrospectively studied. Five-year survival rate was 29% overall; for patients at stage I-II (n = 15) it was 70%, and for patients at stage III-IV (n = 30) it was 12%. In patients given mitotane + chemotherapy survival rate was similar to that observed in patients given chemotherapy alone, and significantly longer than in patients given mitotane alone (p < 0.05). There were no differences in disease-free interval and survival between adjuvant mitotane and no treatment. Optimization of therapeutic protocols in addition to early recognition may improve prognostic aspects of this type of malignancy for which treatment outcome is still unsatisfactory.
Related Concept Videos
Cushing Syndrome I: Introduction
Treatment Resistant Cancers
Cancer Survival Analysis